News

COLUMBUS, Ohio – Increasing numbers of patients with advanced colorectal cancer are living longer, thanks in part to novel targeted drug therapies that work in conjunction with chemotherapy.

“Targeted therapies are like ‘smart bombs,’” said Dr. Tanios Bekaii-Saab, an oncologist at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

“These drugs target the tumor and its surrounding environment, and spare most of the normal tissue from damage.”

Examples of targeted therapies for colorectal cancer include bevacizumab and cetuximab. These drugs are biologically engineered to attack cancer at its molecular roots. The OSUCCC – James is leading or participating in several innovative clinical trials for colorectal cancer using these and other novel targeted therapies.

Buoyed by recent successes, cancer researchers are working to improve the effectiveness of these drugs by testing different combinations and sequences of these drugs in clinical trials, said Bekaii-Saab.

In recent years, the death rate from colorectal cancer has dropped while the average survival has increased – in some cases dramatically, said Bekaii-Saab. He attributes much of that success – particularly for those patients with advanced metastatic cancer that has spread outside their colon and rectum – to the increased use of targeted therapies that attack cancer cells or their surrounding and leave healthy cells alone.

A number of studies published in the last couple of years reported the dramatic successes of bevacizumab and cetuximab and have led to further clinical studies of targeted therapy in colorectal cancer at the OSUCCC – James and elsewhere, Bekaii-Saab said. Those reports concluded that these targeted therapies are “one of the most promising areas of cancer treatment and research,” he said.

Bevacizumab inhibits new blood vessels from forming around the tumor, which in turn makes the blood flow more efficient and chemotherapy delivery more effective in the initial stages of therapy. It also works on starving the tumor by cutting its blow flow in later stages.

Cetuximab targets a protein on the cancer and disables the epidermal growth factor receptor, which prevents cancer cell growth and makes the cancer cells more susceptible to chemotherapy.

“These two targeted agents work really well, and we are now looking at combining them in different ways to see if we can add more benefit to our cancer patients,” Bekaii-Saab said.

Combining bevacizumab with traditional chemotherapy regimens can add an average of five months to survival, Bekaii-Saab said. In some cases, however, survival has been extended three years or more.

“This is a very exciting time in colorectal cancer research,” he said. “We have seen patients respond extremely well to these therapies. Some are five years out and still have a good quality of life.”

About 150,000 people in the United States will be diagnosed with colorectal cancer this year, and more than 57,000 will die from it. Colorectal cancer is the second most common cancer in this country, accounting for about 10 percent of annual cancer deaths. Colorectal cancer refers to the presence of malignant cells in the colon or rectum, both of which are part of the large intestine. The tumors also may spread to other parts of the body.

“The greatest advances in treating colorectal cancer in recent years have come from targeted therapies that seem to work best when combined with chemotherapy,” Bekaii-Saab said. “Of course, early diagnostic screenings, along with preventive measures such as eating right and exercising more, also play a crucial role in improving survival outcomes.”

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of the nation’s leading centers for research on the prevention, detection, diagnosis and treatment of cancer. The OSUCCC – James encompasses six interdisciplinary research programs and includes more than 200 investigators who generate over $100 million annually in external funding. It is a founding member of the National Comprehensive Cancer Network, and OSU’s James Cancer Hospital is consistently ranked by U.S. News & World Report as one of America’s best hospitals for cancer care.

Contact: